These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32776624)

  • 1. Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia.
    Stephen S; Park YA; Chrysostomou A
    Nephrology (Carlton); 2020 Nov; 25(11):845-849. PubMed ID: 32776624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.
    Radbel J; Narayanan N; Bhatt PJ
    Chest; 2020 Jul; 158(1):e15-e19. PubMed ID: 32343968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
    Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
    Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
    Tholin B; Hauge MT; Aukrust P; Fehrle L; Tvedt TH
    J Med Case Rep; 2020 Oct; 14(1):187. PubMed ID: 33054818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.
    Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR
    Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
    Ranger A; Haji R; Kaczmarski R; Danga A
    Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
    Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
    Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectology].
    Lakatos B; Gopcsa L; Gondos E; Riczu A; Várnai Z; Nagy É; Molnár E; Bekő G; Bobek I; Reményi P; Szlávik J; Sinkó J; Vályi-Nagy I
    Orv Hetil; 2020 Jun; 161(26):1070-1077. PubMed ID: 32541085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
    Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
    BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
    Liu B; Li M; Zhou Z; Guan X; Xiang Y
    J Autoimmun; 2020 Jul; 111():102452. PubMed ID: 32291137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome].
    Velasco Puyó P; Moreno L; Díaz de Heredia C; Rivière JG; Soler Palacín P
    An Pediatr (Engl Ed); 2020 Aug; 93(2):132-133. PubMed ID: 32593520
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
    Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
    J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].
    Luo S; Yang L; Wang C; Liu C; Li D
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(2):227-231. PubMed ID: 32391669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.
    Quartuccio L; Sonaglia A; McGonagle D; Fabris M; Peghin M; Pecori D; De Monte A; Bove T; Curcio F; Bassi F; De Vita S; Tascini C
    J Clin Virol; 2020 Aug; 129():104444. PubMed ID: 32570043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics.
    Wang W; Liu X; Wu S; Chen S; Li Y; Nong L; Lie P; Huang L; Cheng L; Lin Y; He J
    J Infect Dis; 2020 Oct; 222(9):1444-1451. PubMed ID: 32601708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome.
    Steinhardt MJ; Wiebecke S; Weismann D; Frantz S; Tony HP; Klinker H; Schmalzing M
    Scand J Rheumatol; 2020 Sep; 49(5):414-416. PubMed ID: 32914670
    [No Abstract]   [Full Text] [Related]  

  • 20. A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece.
    Marinaki S; Tsiakas S; Skalioti C; Lourida P; Argyraki A; Grigorakos K; Boletis I
    Medicina (Kaunas); 2020 Jul; 56(7):. PubMed ID: 32708858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.